• Mira Smart Conferencing
  • Home
  • Table of Contents
  • Advanced Search
 
Advanced Search

Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

  • Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL

Filter

Partial Search: Partial searches may be entered manually by pressing enter in the filter input field.
Author Filter: Selecting one or more Authors from the Author drop down list will filter results by Author last name(s) only.

Displaying 1 - 2 of 2

  • Page:
  • 1

Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age

Author:Wiendl, Heinz   Cohen, Jeffrey   Gold, Ralf   De Seze, Jerome   Robertson, Derrick   Wray, Sibyl   Sacca, Francesco   Zielman, Ronald   Azmon, Amin   King, Miriam   Fantaccini, Simone   Kappos, Ludwig   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.016  

Author Institution:University of Muenster, Muenster, Germany  Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany  University Hospital of Strasbourg, Strasbourg, France  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL  Hope Neurology MS Center, Knoxville, TN  Department (NSRO), University “Federico II” of Naples, Naples, Italy  Novartis Pharma B.V., Amsterdam, Netherlands  Novartis Pharma AG, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  

  • View Abstract
  • View Disclosure

Compliance and Persistence With Ofatumumab Treatment in Patients With Relapsing Multiple Sclerosis in Clinical Trials for Up to 4 Years

Author:Alvarez, Enrique   Hersh, Carrie   Robertson, Derrick   Das Gupta, Ayan   Hu, Xixi   Zielman, Ronald   Boer, Ibolya   Cheadle, Andy   Cohen, Jeffrey   

Session Name:P8: MS Therapeutics 2  

Topic:MS and Inflammatory Disease  

Program Number:P8.002  

Author Institution:Department of Neurology, Rocky Mountain Multiple Sclerosis Center at the University of Colorado , Aurora, CO  Lou Ruvo Center for Brain Health, Cleveland Clinic Mellen Program for MS, Las Vegas, NV  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL  Novartis Healthcare, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V., Amsterdam, Netherlands  Novartis Pharma AG, Basel, Switzerland  Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  

  • View Abstract
  • View Disclosure

Displaying 1 - 2 of 2

  • Page:
  • 1

© 2015 Mira Smart Conference | http://www.mirasmart.com